Daily Stock List
Inovio Pharmaceuticals, Inc. (INO)
StreetAuthority Daily reported yesterday on Inovio Pharmaceuticals, Inc. (INO), The Street, FeedBlitz, Wall Street Resources, SmarTrend Newsletters, Stock Exploder, MajorPennyStocks did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Blue Bell, Pennsylvania, Inovio Pharmaceuticals, Inc., in tandem with their subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. The Company’s clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Inovio's mission is to expand immune system stimulation to revolutionize vaccines. The Company's shares trade on the NYSE.
Inovio Pharmaceuticals' partners and collaborators include the University of Pennsylvania, Merck, ChronTech, the National Cancer Institute, the U.S. Military HIV Research Program, NIH, the HIV Vaccines Trial Network, the University of Southampton, the US Dept. of Homeland Security and the PATH Malaria Vaccine Initiative.
The design of the Company's SynCon® vaccines is to provide universal cross-strain protection against known and newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile.
Inovio Pharmaceuticals' primary focus is on developing revolutionary preventive and therapeutic vaccines for humans. In addition, Inovio has other technologies available for partnering. These include animal applications of their synthetic vaccines and proprietary growth hormone-releasing hormone (GHRH) technologies; gene expression regulating technologies; and a novel small molecule anti-inflammatory drug.
This month, the Company announced clinical results indicating that their VGX-3100 therapeutic synthetic vaccine is capable of not only driving strong immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. Inovio believes that this desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and cervical cancer. Inovio is currently assessing the ability of their DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial.
Last week, Inovio Pharmaceuticals announced that their majority-owned subsidiary, VGX Animal Health, received approval to market LifeTide® SW 5.0, the world's first approved growth hormone releasing hormone (GHRH) therapy for food animals, in New Zealand. LifeTide is a once-in-a-lifetime treatment for female pigs (sows) that has demonstrated major decreases in perinatal mortality of piglets from treated sows compared to untreated sows. The treatment, which increases the number of weaned piglets and results in greater overall meat production, received previous approval in Australia.
Inovio Pharmaceuticals, Inc. (INO), closed Tuesday's trading session at $0.7175, down 0.19%, on 1,143,551 volume with 1,122 trades. The average volume for the last 60 days is 591,137 and the stock's 52-week low/high is $0.35/$0.899.
LuxeYard, Inc. (LUXR)
Greenbackers, Pumps and Dumps, OurHotStockPicks, and Xtremepicks reported recently on LuxeYard, Inc. (LUXR), OTCJournal did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, LuxeYard is an e-commerce website for luxury home furnishings and décor. The members-only flash sale site offers access to unique products sourced from an experienced team at prices up to 70 percent off retail. LuxeYard caters to well informed shoppers with sophisticated tastes. The Company established in 2011 and the LuxeYard site was launched in January 2012. LuxeYard became public via the reverse merger process; they acquired an existing public company with limited operations and became the surviving entity. The Company has their corporate headquarters in Los Angeles, California.
LuxeYard provides access to distinctive, eclectic, and curated apparel and home decor, direct from manufacturers to consumers at discounted prices. The Company is the pioneer of Concierge Buying; this gives members the power to determine the items sold on the site. LuxeYard is also the pioneer of Group Buy that allows them to lower the price by sharing sale items with friends. LuxeYard collaborates with trendsetters and industry insiders to deliver interactivity and content on their pages.
LuxeYard offers household furnishings and goods, including furniture, lighting products, and beddings; and apparel and accessories. LuxeYard conducts weekly flash sale events on their site that feature merchandise from merchants at discounts to retail prices, and deal of the day that consists of offering a single product on their site for a 24-hour period.
In August, LuxeYard announced the appointment of Mr. Jerry Wilkerson, LuxeYard's current CTO/CIO, to the position of Chief Operating Officer (COO). The Company started a search for a replacement CTO, to be filled this month (October). Mr. Wilkerson replaces Mr. Steve Beauregard who departed the Company to pursue other startup endeavors. Jerry Wilkerson has been an executive at LuxeYard since the Company's launch in 2011. He has more than ten years experience in retail technology; he was the founder of HomeLoft, an online discount leather furniture company.
LuxeYard, Inc. (LUXR), closed Tuesday's trading session at $0.13, down 0.78%, on 100,892 volume with 17 trades. The average volume for the last 60 days is 299,310 and the stock's 52-week low/high is $0.101/$2.32.
Central Virginia Bankshares, Inc. (CVBK)
Today we are reporting on Central Virginia Bankshares, Inc. (CVBK), here at the QualityStocks Daily Newsletter.
Central Virginia Bankshares, Inc. is the parent of Central Virginia Bank. The Bank provides community and commercial banking services to individuals and small to medium sized businesses in Virginia. The Company established in 1972 and has their headquarters and main office in Powhatan, Virginia. Central Virginia Bankshares has six additional branch offices: two branches in the adjacent County of Cumberland, three branches in western Chesterfield County, and one branch in western Henrico County. The Company's shares trade on the OTCQB.
Central Virginia Bank's deposit products include checking accounts, savings accounts, interest bearing demand deposits, non-interest bearing demand deposits, money market accounts, certificates of deposits, and other time deposits. The Bank's loan products portfolio consists of consumer demand, time, and installment loans for diverse purposes, including automobile loans, home equity lines of credit, and credit cards.
Their loan products also include commercial business loans, commercial mortgage loans, and real estate construction loans. In addition, Central Virginia Bank provides Internet banking, telephone banking, debit cards, and other ancillary services. This includes the sale of non-deposit investment products. Furthermore, the Bank offers ATMs, travelers checks, safe deposit boxes, deposit transfer, notary public, escrow, drive-in facilities, and other regular banking services.
This past August, Central Virginia Bankshares and Central Virginia Bank announced that the Company recorded net income of $219,000 for the second quarter of 2012. After the effect of unpaid dividends of $161,000 on preferred stock, net income available to common shareholders totaled $58,000 or $0.02 per basic and diluted share. This is in comparison to second quarter of 2011 net income of $94,000. After the effect of dividends of $161,000 on preferred stock, net loss available to common shareholders was $67,000 or $(0.03) per basic and diluted share.
For the six months ended June 30, 2012, the Company recorded net income of $509,000. After the effect of the unpaid preferred stock dividends of $321,000, net income available to common shareholders totaled $188,000 or $0.07 per basic and diluted share. This is in comparison to the six months ended June 30, 2011 net income of $351,000. After the effect of unpaid preferred stock dividends of $321,000, the net income available to common shareholders was $30,000 or $0.01 per basic and diluted share.
Central Virginia Bankshares, Inc. (CVBK), closed Tuesday at $0.70, down 4.11%, on 20,970 volume with 5 trades. The average volume for the last 60 days is 3,103 and the stock's 52-week low/high is $0.57/$1.07.
Laurentian Goldfields, Ltd. (LGF.V)
Today we are reporting on Laurentian Goldfields, Ltd. (LGF.V), here at the QualityStocks Daily Newsletter.
Headquartered in Vancouver, British Columbia, Laurentian Goldfields, Ltd. focuses on the acquisition, exploration and development of high quality gold properties in Canada. The Company's use of leading-edge exploration concepts and techniques has attracted AngloGold Ashanti Ltd., Antofagasta Minerals S.A., Kinross Gold Corp., and Teck Resources to invest in Laurentian as exploration partners and shareholders. Laurentian Goldfields lists on the TSX Venture Exchange.
The Company advances their prospective projects through their internal technical team, their extensive network of exploration industry specialists, and through engaging the financial support of major mining companies via exploration alliances and joint venture agreements.
Laurentian Goldfields is concentrating on their Van Horne Gold Property, located 8 km southwest of Dryden, Ontario in the Kenora Mining District. Laurentian has defined a 5 km long Gold Trend on the Van Horne Property. This trend includes high-grade and bulk-tonnage drill-ready targets. The Company's 2012 focus is further developing this Property.
In 2011, Laurentian secured an option to acquire 100 percent of Teck Resources' interest in the Thundercloud gold property. This property is 50 kilometers southeast of Dryden, Ontario and within the emerging underexplored Wabigoon belt. Recent drilling by Teck, combined with historic exploration suggests that Thundercloud has the potential to host a bulk-tonnage gold deposit.
Laurentian also has the Goldpines property. It underwent staking in early 2010 to cover a hydrogeochemical (HGC) anomaly defined by Laurentian's geological team following an October 2009 HGC survey targeting prospective areas along the contact of the Uchi and English River Geological Subprovinces. The HGC survey detected a greater than 200 km2 area, characterized by anomalous concentrations of gold, antimony, arsenic and other key elements that Laurentian believes to be the alteration footprint of a significant gold mineralization event. The Company's other projects include Maze Lake, Hickson, and Belcourt.
This past July, Laurentian Goldfields announced that they signed a US$1,500,000, two-year strategic exploration alliance with Antofagasta Minerals S.A., a wholly owned subsidiary of Antofagasta plc for generative copper exploration in southern Quebec. The Alliance will utilize Laurentian's extensive technical and exploration expertise as a project generator to identify copper properties for acquisition in specific target areas of Quebec. The guiding of exploration work will be through the establishment of a joint Technical Committee with Laurentian Goldfields acting as Operator.
Laurentian Goldfields, Ltd. (LGF.V), closed Tuesday's session at $0.03, up 20.00%, on 62,000 volume. The stock's 52-week low/high is $0.03/$0.16.
Viper Powersports, Inc. (VPWI)
Emerging Markets, PennyInvest, MadPennyStocks, PennyStockVille, StockRich, StockEgg, BullRally, HotOTC, and CoolPennyStocks reported previously on Viper Powersports, Inc. (VPWI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Viper Powersports, Inc. is a leader in developing, manufacturing and marketing Power Cruisers, V-Twin engines, accessories and aftermarket components through an independent dealer network. These products are targeted at affluent motorcycle enthusiasts. The Company's motorcycles compete in the upscale segment of the heavyweight custom V-Twin cruiser market. Viper Powersports utilizes patented technology using Computer Aided Design (CAD). Founded in 2002, the Company lists on the OTCQB and has their headquarters in Auburn, Alabama.
Viper Powersports' motorcycles are distributed and sold under the Viper brand names by way of their wholly owned subsidiary: Viper Motorcycle Company. Viper Powersports Joint Venture partner is Ilmor Engineering. Ilmor provides technical developmental support for the proprietary 152 cubic inch Viper V-Twin engine.
Viper Motorcycle Company completed the move into their custom-built 63,000 square foot manufacturing facility and World Headquarters in July of 2011. This facility sits on 17 acres in the Auburn Technology Park West. It offers the Company the ability for expansion as their business continues to grow. The city and state provided incentives to Viper. In addition, the move to Auburn provided the ability to create a relationship with the Auburn University Engineering School. Moreover, in the south, in Auburn, the Company has a longer window for riding and testing.
In September 2012, Viper Motorcycle Company announced a marketing agreement with Pro Stock Motorcycle Teams Gottspeed Racing (Rider Michael Ray) and Matt Smith Racing (Rider Matt Smith) for the remainder of the 2012 NHRA Full Throttle Drag Racing Series season. Both teams are qualified for the NHRA Countdown to the Championship.
Yesterday, Viper Motorcycle Company announced that they signed a Distribution Agreement with Urban Moto Imports for exclusive distributorship for Australia and New Zealand.
Mr. Colbert Seagraves, Viper Motorcycle Company's Vice President of Marketing and Racing Operations, stated, "We are extremely pleased to add a group the caliber of Urban Moto Imports to our overseas distributor network. They have been in business for quite sometime and are very successful."
Viper Powersports, Inc. (VPWI), closed Tuesday's trading session at $0.30, even for the day, on 11,500 volume with 3 trades. The average volume for the last 60 days is 12,442 and the stock's 52-week low/high is $0.155/$0.45.
GeoMet, Inc. (GMET)
SmarTrend Newsletters, PennyTrader Publisher, and StreetInsider reported earlier on GeoMet, Inc. (GMET), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, GeoMet, Inc. is an independent energy company with headquarters in Houston, Texas. The Company primarily engages in the exploration for, and development and production of, natural gas from coal seams (coalbed methane -CBM). GeoMet goes after projects with large, high impact resource potential that take advantage of the Company's significant CBM expertise. Founded in 1985, GeoMet has a history of developing large-scale projects with low finding and development costs and low project life operating costs. CBM has recognition, domestically and worldwide, as a significant source of gas reserves.
The Company's principal operations and producing properties are located in Alabama, Virginia and West Virginia. In addition, GeoMet controls non-producing coalbed methane rights, principally in Alabama, Virginia, and West Virginia. Their Technical staff has developed five large-scale CBM projects in four separate basins in the United States (Black Warrior, Raton, Central Appalachia, and Cahaba basins.)
At December 31, 2011, GeoMet controlled approximately 195,000 net acres of coalbed methane and oil and natural gas development rights, primarily in Alabama, West Virginia, and Virginia. The Company's major holdings consist of approximately 39,000 net acres in Alabama and approximately 95,000 net acres in the central Appalachian Basin.
GeoMet's proved reserves as of December 31, 2011 (as estimated by DeGolyer and MacNaughton and Ryder Scott Company, L.P., independent reservoir engineering firms) were approximately 198.1 Bcf. The 2011 proved reserves were 100 percent coalbed methane and 95 percent were developed. Approximately 36 percent of year-end 2011 proved reserves are in Alabama and 61 percent are in the central Appalachian Basin.
In the Central Appalachian Basin, GeoMet is the operator of 300 vertical wells. They are also the operator of 89 horizontal wells and have a 33.0 percent average working interest in 67 non-operated horizontal wells. In the Black Warrior and Cahaba Basins in Alabama, the Company is the operator of 252 vertical wells for which they own a 100 percent working interest. Moreover, they own working, overriding royalty or royalty interests in 1,103 non-operated vertical wells.
In September, GeoMet announced that their annual meeting of stockholders would take place on November 8, 2012. Stockholders of record at the close of business on September 24, 2012 will be entitled to notice of and to vote at the Annual Meeting.
GeoMet, Inc. (GMET), closed Tuesday's trading at $0.1650, up 3.12%, on 25,700 volume with 8 trades. The average volume for the last 60 days is 44,530 and the stock's 52-week low/high is $0.12/$0.24.
Rainbow Coral Corp. (RBCC)
OTC Stock Pick and FeedBlitz reported this month on Rainbow Coral Corp. (RBCC), Best Microcap Stock did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Based in Florida, Rainbow Coral Corp. continually looks for new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. Rainbow Biosciences is a new company focusing on identifying, developing and marketing the next generation of bioscience solutions for the healthcare and scientific communities. Rainbow Coral lists on the OTC Bulletin Board.
Rainbow Coral has acquired a new equity interest in Nano3D Biosciences, Inc. (n3D). Nano3D's new product, the Bio-Assembler, will soon allow researchers to shorten significantly the development timeline for advanced new drugs and treatments.
The Company's Rainbow BioSciences subsidiary has executed a Letter of Intent (LOI) to advance Amarantus BioSciences, Inc.'s (OTCBB: AMBS) Parkinson's disease program. This program consists of an early detection diagnostic blood test and a disease-modifying protein drug candidate. The companies plan to work together to deliver NuroPro. This is a new early-detection diagnostic blood test. The Company believes it could soon prove vital to successfully treating Parkinson's and other neurological diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies.
This month, Rainbow Coral CEO, Mr. Patrick Brown, said that the awarding of the Nobel Prize recently to two scientists who have revolutionized stem cell research could lead to an influx of investment capital into the industry. Japan's Shinya Yamanaka and Britain's John Gurdon were jointly awarded the medicine prize for proving that adult cells can be regressed back into stem cells. These create cells known as induced pluripotent stem cells (iPS) that allow for stem-cell research that does not necessitate the destruction of a fetus.
Rainbow Coral is presently working to help speed up the research of Yamanaka and others into potential cures for deadly diseases through commercializing the use of an innovative new technology in select markets worldwide. The Company engaged Regenetech in discussions regarding the potential acquisition of a license to perform cell expansion using Regenetech's Rotary Cell Culture System™. Rainbow Coral's intention is to offer the new technology to help kick start billions of dollars worth of research in an industry presently dominated by Amgen, Inc. (AMGN), Celgene Corp. (CELG), Genzyme Corp. (NASDAQ:GENZ) and Gilead Sciences, Inc. (GILD).
Last week, Rainbow BioSciences announced that they prepared a Joint Venture term sheet for presentation to Amarantus BioSciences. If Amarantus approves the term sheet, both parties will move forward with a Joint Venture Agreement as soon as possible, said RBCC CEO Patrick Brown. The first project planned for the Joint Venture will be the commercialization of NuroPro.
Rainbow Coral Corp. (RBCC), closed Tuesday's trading session at $1.07, down 6.96%, on 13,605 volume with 12 trades. The average volume for the last 60 days is 15,273 and the stock's 52-week low/high is $0.51/$20.00.
ULURU, Inc. (ULUR)
We are highlighting ULURU, Inc. (ULUR), here at the QualityStocks Daily Newsletter.
ULURU, Inc.'s dedication is to developing and commercializing a wide spectrum of innovative wound care and muco-adhesive film products. The basis of these is on the Company's patented Nanoflex® and OraDisc™ technologies. ULURU's objective is improving outcomes for patients, health care professionals and providers. The Company's shares trade on the OTCQB. ULURU has their headquarters in Addison, Texas.
ULURU's business strategy includes developing and commercializing a customer focused portfolio of innovative wound care products to treat the various phases of wound healing. Their strategy also includes developing the oral-transmucosal technology and generating revenues via multiple licensing agreements.
The Company has their Altrazeal® product - a transforming powder dressing with Nanoflex® technology. They developed and they commercialize Altrazeal® for the management of exuding wounds. Altrazeal® powder particles are the result of a rigorous development program where the product has undergone engineering to provide the necessary wound-healing benefits. The design of the exact scale and proportion is to provide optimal oxygen and vapor transpiration, and microbial impermeability, tensile strength, and flexibility.
Furthermore, ULURU has their Aphthasol® 5% Paste (amlexanox). Aphthasol® contains 5% amlexanox in an adhesive oral paste. Aphthasol® is FDA approved and indicated for the treatment of aphthous ulcers in people with normal immune systems. The Company has also developed OraDisc™ A. This is a novel mucoadhesive, water-erodible disc incorporating 2mg of amlexanox for the treatment and prevention of aphthous ulcers. OraDisc™ is a polymer solid dosage form used to deliver amlexanox to the mucosal tissue.
ULURU also has their OraDisc™ B. This is a mucoadhesive erodible disc; it contains 15 mg of benzocaine that has undergone development for the treatment of oral pain. Moreover, the Company has their OraDisc™ W- Erodible Whitening Strip for Teeth. This patented delivery strip for whitening teeth completely erodes. This proprietary tooth-whitening product consists of a laminated bilayer strip that uses the OraDisc™ technology. The layer that is applied to the teeth contains hydrophilic polymers and the active whitening ingredient. The outer layer consists of a blend of hydrophilic and hydrophobic polymers. The residence time of the strip on the teeth is controlled through the formulation.
Recently, ULURU announced the signing of a Binding Term Sheet for an extensive strategic relationship with Melmed Holding AG. Melmed will make an equity investment in ULURU of $2 million at a fixed price of 0.40 cents per share of common stock (5 million shares) and will receive a warrant to purchase 3 million shares of common stock at an exercise price of 0.60 cents and a term of one year. Melmed will enter into a worldwide license agreement with ULURU for certain oral and dental applications of the Company's erodible film technology, OraDisc™. ULURU will receive a 25 percent interest in a subsidiary that will be established to license the OraDisc™ rights and will receive a royalty on global sales.
ULURU, Inc. (ULUR), closed Tuesday's trading session at $0.201, down 7.80%, on 67,133 volume with 11 trades. The average volume for the last 60 days is 62,039 and the stock's 52-week low/high is $0.05/$0.40.
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.45, off by 6.25%, on 18,500 volume with 10 trades. The stock’s average daily volume over the past 60 days is 7,919, and its 52-week low/high is $0.41/$1.87.
GlobalWise Investments, Inc. announced sponsorship and participation in two upcoming conferences hosted by national managed print industry leading publication, The Imaging Channel (www.TheImagingChannel.com). These free events are being co-sponsored by the company's wholly-owned cloud-based Enterprise Content Management systems subsidiary, Intellinetics, Inc., as well as their recently announced channel partner, MWA Intelligence, Inc., one of the largest domestic IT infrastructure providers for copier dealer Managed Print Service companies. The first Imaging Channel Conference is slated for October 31st in Chicago with the second being held the week after on November 7th in Santa Monica. Both conferences will draw together some of the top industry leaders in software, IT, and managed services.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
GlobalWise Announces New Channel Partnership With Level Seven
GlobalWise Announces Appointment of Kendall D. Gill to Chief Financial Officer Position
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.006, up 71.43%, on 141,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 221,384, and its 52-week low/high is $0.001/$0.018.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Consorteum Completes Acquisition of Tarsin Inc.
Teletouch Communications, Inc. (TLLE)
The QualityStocks Daily Newsletter would like to spotlight Teletouch Communications, Inc. (TLLE). Today, Teletouch Communications, Inc. closed trading at $0.48, up 17.07%, on 2,599 volume with 2 trades. The stock’s average daily volume over the past 60 days is 26,227, and its 52-week low/high is $0.253/$0.89.
Teletouch Communications, Inc. (TLLE) offers a comprehensive suite of wireless telecommunications solutions, including cellular, GPS-telemetry, and wireless messaging. Founded in 1964, the company provides its products and services to consumers, businesses, and government agencies, operating a chain of 11 retail and authorized agent stores, in conjunction with its direct sales force, call center operations, and various retail eCommerce websites.
Through its wholly owned subsidiary, Progressive Concepts, Teletouch operates a national distribution business, PCI Wholesale, primarily serving Tier-1 (AT&T, T-Mobile, Verizon, Sprint) cellular carrier agents, Tier-2, Tier-3, and rural carriers, as well as auto dealers and smaller consumer electronics retailers. The subsidiary's international sales coverage includes Canada, Mexico, Brazil, Singapore, and China.
The company is currently focusing on growing its core wholesale distribution business. The business plan being executed includes selling non-core corporate assets and reviewing potential acquisition opportunities. Operators and retailers of all sizes are seeking new sources of revenue at lower costs, creating a large opportunity to provide great products and value-added distribution capabilities at competitive prices.
Teletouch's management team has extensive experience in financing, acquiring, and operating retail, wireless and other related companies. Robert McMurrey, Chairman and CEO, guided Teletouch's original external expansion with the completion of over 15 acquisitions to date. Today, the company supports over 60,000 wireless customers, leveraging its long-standing relationships and global presence to drive future earnings growth. Disclaimer
Teletouch Communications, Inc. Blog
Teletouch Communications, Inc. News:
Teletouch Reports First Quarter 2013 Fiscal Year Results
Teletouch Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
Teletouch Announces Distribution Agreement with Unimax Communications for Sales of UMX Branded Cellular Handsets in North America
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.26, even with yesterday's close, on 103,256 volume with 27 trades. The stock’s average daily volume over the past 60 days is 110,755, and its 52-week low/high is $0.21/$0.71.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
International Stem Cell Corp to Participate in Upcoming Investor Conference
International Stem Cell Corp Granted Key Patent for Liver Disease Program
GlobalWise Investments announced this morning that its wholly owned subsidiary Intellinetics will be sponsoring and participating in two conferences hosted by the national managed print industry leading publication The Imaging Channel (www.TheImagingChannel.com). Intellinetics is a leading-edge technology company focused on the design, implementation, and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors.
Both conferences are free events co-sponsored exclusively by Intellinetics and their recently announced channel partner MWA Intelligence, Inc. (MWAi). MWAi is one of the largest IT infrastructure providers for copier dealer Managed Print Service companies in the United States. MWAi CEO Mike Stramaglio chose GlobalWise to participate in the conference as the only ECM provider in attendance. Participants at the two conferences will learn new and exciting ways Content Management applications can reduce operating costs, increase productivity, and streamline processes for greater efficiency.
The first Imaging Channel Conference will be held next week on October 31st in Chicago with the second conference held on November 7th in Santa Monica. Leaders in software, IT, and managed services will discuss how unified systems increase advanced collaboration and communications to help organizations realize impressive cost savings and build a more sustainable IT infrastructure. The attendance of approximately 50 executives at each show is expected to be a split mix of managed print dealers and end-users interested in implementing content management into their organization. With each dealer representing on average 3,500 end-user clients, GlobalWise will be able to showcase their industry leading ECM software to a large new audience of potential channel partners and end-user clients.
“The relationship with MWAi is opening many doors for GlobalWise to showcase our cloud-based ECM software,” commented William “BJ” Santiago, CEO of GlobalWise. “By co-sponsoring these two Imaging Channel conferences, GlobalWise is on stage with one of the largest and most respected IT infrastructure organizations in the world, which provides increased credibility in the managed print space. This venue is a fantastic marketing and sales outreach program to show IT professionals how cloud-based managed print services create significant efficiency, flexibility and time savings for organizations while enabling more productive and profitable business.”
To learn more about GlobalWise and its software solutions, visitwww.GlobalWiseInvestments.com
When it comes to the evolving world of healthcare, there is no brighter light than stem cell technology. It’s a field that is seen as offering more creative potential for the curing and preventing of disease than could be imagined only a decade ago. The power of stem cell technology has always resided in its unique advantages over traditional approaches, based upon its ability to actually regenerate new and compatible cells. It opens the door to possibilities that simply don’t apply to other treatments.
Human parthenogenetic stem cells (hpSCs), developed by International Stem Cell Corp., offer an unmatched combination of advantages that differentiates them from all other sources of stem cells. At the heart of this difference is the fact that parthenogenetic stem cells are sourced from unfertilized human eggs, created by chemically stimulating the ova to begin division. The eggs are not fertilized and no viable embryo is created or destroyed, totally sidestepping the controversy that is inherent with the use of human embryonic stem cells.
Because of the way they are generated, parthenogenetic stem cells also have a number of other advantages over conventional stem cell sources.
• Parthenogenetic stem cells have a duplicate set of human leukocyte antigen (HLA) genes, which significantly reduces the possibility of the derived cells being rejected by a patient’s immune system. As a result, a single cell line can be suitable for the treatment of millions of people, and a relatively small number of such cell lines could provide “immune matched” cells to a significant percentage of the world’s population.
• Parthenogenetic stem cells do not face the regulatory scrutiny associated with standard induced pluripotent stem cells, which are differentiated cells that are chemically or otherwise driven back to earlier developmental stages involving modifications in gene expression that may have unknown biological impacts.
• Unlike adult stem cells, parthenogenetic stem cells are pluripotent and not as limited in their ability to differentiate or proliferate. They can be used to generate heart, liver, and all other kinds of cells, for use in treatment or research.
For additional information, visit www.InternationalStemCell.com
Uranerz Energy, the rapidly developing domestic mining firm which has fully embraced the future of in-situ recovery (ISR) at their Nichols Ranch project in Wyoming’s heavily mineralized Powder River Basin (also the current de facto extraction method regionally), reported issuance today of the Class I Underground Injection Control permit for the deep disposal well at Nichols from Wyoming’s Department of Environmental Quality.
This key document represents the final hurdle to be leapt over by URZ in the run up to commercial operations at the Nichols Ranch ISR Uranium Project, and the company has cleared it with that same agility that has served them so well thus far. Uranerz Energy has assembled an impressive land position in the region, with NI 43-101 reportage covering seven of their 30 plus uranium projects in the Powder River Basin area. A simple calculation of the total regional measured and indicated resources under URZ’s thumb is 15.7M lbs eU3O8 at an average grade of 0.103% (3.34M inferred, grading 0.111% on average), with Nichols being above average grade-wise at 0.114%, on a measured and indicated resource of some 2.95M lbs.
President and CEO of URZ, Glenn Catchpole, couldn’t help but show his zeal for the company’s position in the race to become the next big name in domestic ISR uranium next year as the first new uranium mine in Wyoming in 18 years is set to begin operating. Catchpole asserted that installation of the two deep disposal wells this winter would be the next major task for the company, with ancillary completion of remaining construction work also on the docket.
Huge news for URZ shareholders, who have tremendous value to realize as the project is licensed for annual output of up to 2M pounds. Initial post ramp up output projections are 600k to 800k lbs and the project itself will essentially become the epicenter of URZ’s wider regional uranium operations. The uranium opportunity in the Powder River Basin is massive and with multiple global factors set to steadily drive the price of uranium, like Japan’s restarted energy infrastructure, tightening global supply amid expanding footprints in Asia, and our own continued use of nuclear, which account for upwards of 19.2% of total domestic energy supply (number one emission-free source), URZ is well positioned to do serious long-term growth.
The near-term profit taking potential of ISR is the hot ticket though and the tightened uranium supply issue has been crying out for precisely such an efflorescence of domestic entrepreneurship as is realizable via such ISR uranium production. The improved economic and logistical vectors created by a network of regional projects constitutes a mounting return window for CAPEX, and Uranerz is doing shareholders another favor by teaming up with the biggest public uranium company around, Cameco, to ensure processing envelopes are sealed. The company has even developed long-term sales contracts to uptake planned production with two of the biggest domestic utilities.
VP of Environment, Health, and Safety for URZ, Mike Thomas, commended the team for successfully concluding the lengthy regulatory process which has cleared the way for construction/operation of the uranium mine. To look at the way URZ has handled things, you wouldn’t even know this is the company’s first ISR mine.
More information on Uranerz Energy Corp. can be had by visiting the company’s website at: www.Uranerz.com
PositiveID Corp., an emerging growth company and developer of airborne bio-threat detection systems for America’s homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing, today provided a third quarter 2012 business update to its stockholders. The Company continues to focus on the BioWatch Generation 3, Phase II procurement. In September, the Department of Homeland Security (“DHS”) announced a revised procurement strategy for BioWatch Generation 3, Phase II, which will consist of a two-stage procurement including two to three years of testing estimated at $89 million. A draft request for proposal (“RFP”) for the first stage is scheduled to be released in the fourth quarter of calendar 2012.
William J. Caragol, Chairman and CEO of PositiveID, stated, “To position the Company for the first stage of the revised procurement strategy for BioWatch Generation 3, Phase II, we are actively involved in discussions with several potential strategic partners, including both manufacturing partners and systems integration partners. We are focused on trying to bring those discussions to a strategic agreement during the fourth quarter. We also plan in the coming weeks to update stockholders on the progress of our second half of 2012 goals, which we announced in our mid-year update.”
With its acquisition of Microfluidic Systems in May 2011, PositiveID added airborne pathogen detection, rapid clinical diagnostics and sample preparation applications to its business. PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) is a bioaerosol monitor with fully integrated systems with sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins with results in as little as two hours. M-BAND was developed under a competitive award from the DHS Science & Technology Directorate (“S&T”) and was the only system of its kind demonstrated previously in the field under the DHS S&T BAND Program.
The total procurement for BioWatch Generation 3, Phase II, is estimated at $3.1 billion. The goal of BioWatch Generation 3, Phase II is to obtain a fully autonomous networked biodetection capability that will be deployed, operated, and sustained, both indoor and outdoor, in selected U.S. BioWatch jurisdictions to continuously monitor the air for agents of biological concern. The revised strategy for BioWatch Generation 3, Phase II, will consist of a two-stage procurement. Stage 1 will be for Performance Testing of candidate systems and may result in the award of multiple contracts depending on the technical merits of proposals submitted and the availability of funding. Stage 2 will be a separate competition for Low Rate Initial Production, Operational Testing and Evaluation, Full Rate Production, Deployment, Sustainment and Disposal. To be considered for the Stage 2 award, a company will need to demonstrate a design maturity and data set equivalent to that of Stage 1 participants.
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund